Reply:

REFERENCES

1. 1.↵
   2. Sourbron SP,
   3. Buckley DL

   . On the scope and interpretation of the Tofts models for DCE-MRI. Magn Reson Med 2011;66:735–45 doi:10.1002/mrm.22861 pmid:21384424

   CrossRefPubMed
2. 2.↵
   2. Bergamino M,
   3. Saitta L,
   4. Barletta L, et al

   . Measurement of blood-brain barrier permeability with T1-weighted dynamic contrast-enhanced MRI in brain tumors: a comparative study with two different algorithms. ISRN Neurosci 2013;2013:905279 doi:10.1155/2013/905279 pmid:24959569

   CrossRefPubMed
3. 3.↵
   2. Lecler A,
   3. Balvay D,
   4. Cuenod CA, et al

   . Quality-based pharmacokinetic model selection on DCE-MRI for characterizing orbital lesions. J Magn Reson Imaging. 2019 Apr 15. [Epub ahead of print] doi:10.1002/jmri.26747 pmid:30989761

   CrossRefPubMed
4. 4.↵
   2. Heye AK,
   3. Thrippleton MJ,
   4. Armitage PA, et al

   . Tracer kinetic modelling for DCE-MRI quantification of subtle blood-brain barrier permeability. Neuroimage 2016;125:446–55 doi:10.1016/j.neuroimage.2015.10.018 pmid:26477653

   CrossRefPubMed
5. 5.↵
   2. Thrippleton MJ,
   3. Backes WH,
   4. Sourbron S, et al

   . Quantifying blood-brain barrier leakage in small vessel disease: review and consensus recommendations. Alzheimers Dement 2019;15:840–58 doi:10.1016/j.jalz.2019.01.013 pmid:31031101

   CrossRefPubMed